[O19] Oral Session 19　TR・臨床薬理
【E】

[O19-5] Peripheral and Tumoral Immune Activity in the Expansion Part of the First-in-Human DuoBody^®-PD-L1x4-1BB (GEN1046) Trial

^○Santiago Ponce Aix¹, Emiliano Calvo², Victor Moreno³, Guzman Alonso⁴, Andres Cervantes⁵, Suresh S. Ramalingam⁶, Jose Trigo⁷, Patricia Lorusso⁸, Muhammad Furqan⁹, Daniel Cho¹⁰, Alexander Muik¹¹, Eleni Lagkadinou¹¹, Özlem Türeci¹¹, Nora Pencheva¹², Ulf Forssmann¹¹, Ugur Sahin¹¹, Tahamtan Ahmadi¹³, Brandon Higgs¹³, Maria Jure-Kunkel¹³, Ignacio Melero¹⁴ (1.Hospital Universitario 12 de Octubre, Madrid, Spain, 2.START Madrid-CIOCC, Madrid, Spain, 3.START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain, 4.Vall d’Hebron Institute of Oncology, Barcelona, Spain, 5.University Hospital of Valencia, Valencia, Spain, 6.Winship Cancer Institute of Emory University, Atlanta, GA, USA, 7.Hospital Universitario Virgen de la Victoria, Málaga, Spain, 8.Yale Cancer Center, New Haven, CT, USA, 9.University of Iowa, Iowa City, IA, USA, 10.NYU Langone Health Tisch Hospital, New York, NY, USA, 11.BioNTech SE, Mainz, Germany, 12.Genmab A/S, Copenhagen, Denmark, 13.Genmab, Princeton, NJ, USA, 14.Clinica Universidad de Navarra, Pamplona, Spain)